Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...

The Obesity Association, a division of the American Diabetes Association (ADA), has issued new standards of care on the ...

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Novo Nordisk A/S (NOVO:CA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM ESTCompany ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

Novo Nordisk (NYSE: NVO) was once the top player in the weight loss drug market. The company's medicine, Wegovy, practically ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.